<![CDATA[In pharmaceutical manufacturing, inefficiencies such as waiting times, excessive material usage, and packaging defects can significantly impact productivity and quality. This study adopts a Lean Six Sigma approach, integrating lean manufacturing and six sigma methodologies, to systematically address these challenges. Through Process Activity Mapping (PAM), it was determined that value-added (VA) activities account for approximately 63% of total production activities, while non-value-added (NVA) and essential non-value-added (ENVA) activities contribute about 34% and 4%, respectively. Critical waste was identified using the genba shikumi method, followed by Failure Modes and Effects Analysis (FMEA) to determine Risk Priority Numbers (RPNs). Fuzzy logic was applied to prioritize the suggested improvements for more accurate risk assessments. Key recommendations based on Fuzzy RPN rank include, enhancing bulk product quality before printing, implementing rigorous inspections of the printing process, optimizing machine utilization, and adjusting production schedules using the Shortest Processing Time (SPT) method.]]>
Copyrights © 2024
